Global Vaccine Adjuvants Market

Global Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route) - Industry Forecast 2024-2031


Report ID: SQMIG35I2155 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 60 | Figures: 75

Global Vaccine Adjuvants Market Insights

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% in the forecast period (2024-2031).

The growing prevalence of life-threatening diseases such as cervical cancer, Human Papillomavirus (HPV), HIV, and tuberculosis, has led to an increased demand for adjuvants. These adjuvants play a crucial role in enhancing the efficacy of vaccines against these infectious diseases. Furthermore, there is a rising focus on developing vaccines with long-lasting immunization effects to combat existing and emerging diseases. This emphasis on sustained protection has further fueled the demand for adjuvants in the market. Adjuvant research has become increasingly important in the development of vaccines, as innovative vaccine antigens often exhibit inadequate immunogenicity on their own. The market growth is also attributed to the increasing utilization of recombinant and synthetic vaccines. These advanced vaccines rely on adjuvants to enhance their effectiveness, thereby driving the expansion of the market in the upcoming years. Major players in the industry are actively involved in the discovery and development of new adjuvants to combat fatal diseases. Notably, there are promising products like AS01, ISCOM & ISCOMMATRIX, and AS02 that are currently undergoing clinical trials. The introduction of these pipeline drugs is expected to further propel the market growth. In the United States, a developed country with a significant population and a high influx of travelers, the demand for immunization is substantial. This demand is primarily driven by the need to ensure the safety and well-being of the local population. Moreover, favorable government initiatives aimed at immunizing people against serious diseases are anticipated to contribute to market growth. An example of such an initiative is the program initiated by the National Institute of Allergy and Infectious Diseases, which focuses on advancing the development and utilization of adjuvants for human use.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% in the forecast period (2024-2031).

The global vaccine adjuvants market is characterized by a diverse range of companies striving to innovate and meet the growing demand for adjuvant products. Market players are engaged in extensive research and development activities to enhance the effectiveness and safety of adjuvants. Additionally, partnerships, collaborations, and acquisitions are common strategies adopted by companies to strengthen their market position. The competitive environment fosters a continuous drive for technological advancements, improved manufacturing processes, and the development of novel adjuvant formulations, contributing to the overall growth and competitiveness of the market. 'CSL Limited (Australia)', 'GlaxoSmithKline plc (United Kingdom)', 'Novavax, Inc. (US)', 'SEPPIC (France)', 'Agenus Inc. (US)', 'InvivoGen (US)', 'Brenntag Biosector (Denmark)', 'Avanti Polar Lipids, Inc. (US)', 'Vaxine Pty Ltd. (Australia)', 'SPI Pharma (US)', 'OZ Biosciences (France)', 'CureVac AG (Germany)', 'Adjuvatis (France)', 'Advanced BioAdjuvants Corporation (US)', 'Adjuvance Technologies Inc. (US)', 'SDA Bio (Italy)', 'Bio Products Laboratory Ltd. (United Kingdom)', 'GSK Vaccines GmbH (Germany)', 'Mucosis B.V. (Netherlands)', 'NanoBio Corporation (US)'

One key driver for the growth of the global vaccine adjuvants market is the increasing focus on the development of innovative vaccines against emerging and existing diseases. As new infectious diseases continue to emerge and existing ones evolve, there is a growing need for vaccines with enhanced immunogenicity and long-lasting efficacy. Adjuvants play a crucial role in boosting the immune response and improving vaccine effectiveness. The demand for vaccine adjuvants is driven by the imperative to develop advanced vaccines that can effectively combat these evolving and challenging diseases.

The rising need for innovative adjuvant formulations is a significant trend in the world market for vaccine adjuvants. As there is a greater need for effective vaccines, researchers are creating and implementing cutting-edge adjuvant technologies to improve vaccine efficacy and durability. The use of cutting-edge adjuvant substances and delivery technologies that promote potent immune responses while minimising negative effects is included in this.

North America dominated the global vaccine adjuvants market. The United States is a developed country with a substantial population, resulting in a high demand for immunization and vaccine-related products. Additionally, the country experiences a large influx of travelers, which further emphasizes the importance of immunization to ensure public health and safety. Furthermore, the United States has a well-established healthcare infrastructure and favorable government initiatives that support immunization programs, thereby driving the demand for vaccine adjuvants.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Vaccine Adjuvants Market

Product ID: SQMIG35I2155

$5,300
BUY NOW GET FREE SAMPLE